Od Alberta Hofmanna po 4-Pro-MET: historie výzkumu

Historie výzkumu tryptaminů začíná jízdou na kole. 19. dubna 1943 projel Albert Hofmann pod vlivem LSD – ergolinu, nikoli tryptaminu v užším smyslu, ale jiskry pro psychedelický výzkum – Basilejí. Následovalo 80 let výzkumu, zákazů, renesance a vývoje látek jako 4-Pro-MET. Od Hofmannových laboratoří u Sandozu po syntetické tryptaminy 21. století.

Albert Hofmann synthesized LSD (lysergic acid diethylamide) at Sandoz Laboratories in Basel, Switzerland in 1938. Five years later came the accident that changed everything. On April 19, 1943 – now commemorated as "Bicycle Day" – Hofmann absorbed a small quantity through his skin and experienced altered perception during his ride home. LSD is a lysergamide, not a tryptamine. But Hofmann's discovery cracked open the door to systematic psychedelic research.

Tryptamines came next. In 1958, Hofmann synthesized psilocybin and psilocin from Psilocybe mexicana mushrooms. By 1960, he'd determined their chemical structures and developed synthetic production methods. These discoveries put 4-substituted tryptamines on the map alongside lysergamides and phenethylamines. And the research boom that followed was staggering: between 1950 and 1970, approximately 1,000 scientific papers were published on psychedelic tryptamines, and an estimated 40,000 patients received psilocybin or LSD in therapeutic settings.

Alexander 'Sasha' Shulgin (1925–2014) posunul Hofmannovu práci na systematickou úroveň. Ve své soukromé laboratoři v Kalifornii syntetizoval a testoval stovky fenetylaminu a tryptaminů – včetně 4-HO-MET, aktivního metabolitu 4-Pro-MET.

TiHKAL (1997) dokumentoval 55 tryptaminů se syntézními postupy a protokoly vlastních pokusů. O 4-HO-MET (záznam č. 21) Shulgin napsal: 'Qualitatively a lot like psilocin. I started within the first half-hour, and at the max, I felt the same alteration of color and form' – dávka 10–20 mg, trvání 4–6 hodin.

Jeho přístup byl jednoduchý a geniální: změnit jednu proměnnou (např. N-substituci), zbytek ponechat konstantní, dokumentovat účinky. To položilo základ moderního výzkumu vztahů struktura-aktivita (SAR) u tryptaminů. 4-Pro-MET stojí v této tradici: variuje ester na pozici 4 (propionyloxy místo acetyloxy) při stejném N-methyl-N-ethylovém vzoru.

The modern psychedelic renaissance began in 2006 when Roland Griffiths' team at Johns Hopkins published their landmark psilocybin study – demonstrating its ability to occasion mystical-type experiences with lasting positive effects. Clinical trials followed fast: by 2026, over 15 Phase II/III trials are active or completed for psilocybin alone, targeting treatment-resistant depression, PTSD, alcohol use disorder, and end-of-life anxiety.

The research chemical market expanded in parallel. 4-HO-MET appeared as a designer substance around 2008, 4-AcO-MET and 4-AcO-DMT gained popularity through the mid-2010s, and 4-Pro-MET emerged in August/September 2025 as the latest iteration of the 4-substituted tryptamine prodrug strategy. Each compound applies Shulgin's foundational chemistry to generate legal variants with predictable pharmacological profiles.